Novanta Inc. (NASDAQ:NOVT – Get Free Report) CEO Matthijs Glastra sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $150.43, for a total value of $1,128,225.00. Following the completion of the sale, the chief executive officer owned 42,761 shares in the company, valued at $6,432,537.23. This represents a 14.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Matthijs Glastra also recently made the following trade(s):
- On Friday, April 17th, Matthijs Glastra sold 6,500 shares of Novanta stock. The shares were sold at an average price of $130.05, for a total value of $845,325.00.
Novanta Stock Performance
NASDAQ:NOVT traded up $0.27 on Thursday, hitting $155.71. The company’s stock had a trading volume of 694,293 shares, compared to its average volume of 438,179. The company has a current ratio of 3.56, a quick ratio of 2.80 and a debt-to-equity ratio of 0.15. The stock has a fifty day moving average of $126.79 and a two-hundred day moving average of $126.01. The firm has a market capitalization of $5.55 billion, a P/E ratio of 112.83 and a beta of 1.62. Novanta Inc. has a one year low of $98.27 and a one year high of $165.56.
Wall Street Analyst Weigh In
NOVT has been the topic of a number of recent research reports. Robert W. Baird increased their target price on Novanta from $144.00 to $173.00 and gave the stock an “outperform” rating in a research note on Wednesday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Novanta in a research note on Friday, April 17th. Wall Street Zen lowered Novanta from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, Zacks Research upgraded Novanta from a “strong sell” rating to a “hold” rating in a research note on Friday, January 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $173.00.
View Our Latest Analysis on Novanta
Institutional Investors Weigh In On Novanta
Large investors have recently added to or reduced their stakes in the stock. Pilgrim Partners Asia Pte Ltd acquired a new stake in Novanta during the third quarter worth approximately $36,000. Allworth Financial LP grew its position in Novanta by 978.4% during the fourth quarter. Allworth Financial LP now owns 399 shares of the technology company’s stock worth $47,000 after buying an additional 362 shares in the last quarter. Danske Bank A S acquired a new stake in Novanta during the third quarter worth approximately $40,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Novanta in the 3rd quarter valued at $40,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Novanta by 120.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 427 shares of the technology company’s stock valued at $51,000 after purchasing an additional 233 shares in the last quarter. Institutional investors and hedge funds own 98.35% of the company’s stock.
Novanta Company Profile
Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.
Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.
Featured Articles
- Five stocks we like better than Novanta
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
